Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

495
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
495
Probability Laws01:49

Probability Laws

29.7K
Overview
29.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-minute walk test as a practical screening tool for detecting exertional hypoxemia in fibrotic interstitial lung disease: a real-world cohort study.

Scientific reports·2026
Same author

A culturally adapted online Mediterranean diet intervention for metabolic dysfunction-associated steatotic liver disease (TIMA): study protocol for a randomized controlled trial.

Trials·2026
Same author

Dual PI3K/AKT/mTOR and CDK4/6 inhibition suppresses survivin to overcome uterine dedifferentiated endometrial carcinoma.

Cancer gene therapy·2026
Same author

Diagnostic accuracy of MDCT for preoperative peritoneal cancer index estimation in advanced ovarian cancer undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC): a Sugarbaker-based analysis.

European radiology·2026
Same author

Psychometric properties and usability of a gamified digital task system for assessing attention and hand function in stroke rehabilitation.

Digital health·2026
Same author

Plasma proteomic and machine learning models for differentiating idiopathic pulmonary fibrosis and connective tissue disease-associated interstitial lung disease: findings from a prospective cohort.

Respiratory research·2026

Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.8K

Estimation and approximation approaches for biosimilar index based on reproducibility probability.

Lan-Yan Yang1, Chyong-Huey Lai

  • 1a Biostatistics and Informatics Unit, Clinical Trial Center , Chang Gung Memorial Hospital , Taoyuan , Taiwan.

Journal of Biopharmaceutical Statistics
|July 18, 2014
PubMed
Summary

Quantitative evaluation for biosimilarity is crucial for new biosimilar products. This study introduces a novel method using reproducibility probability to estimate biosimilarity index and its lower bound, improving assessment accuracy.

Keywords:
Biosimilar indexBiosimilarityLower boundNoncentral t-approximationPower estimation

More Related Videos

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

1.1K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Related Experiment Videos

Last Updated: Apr 26, 2026

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.8K
Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

1.1K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Area of Science:

  • Biopharmaceutical analysis
  • Quantitative biosimilarity assessment
  • Statistical methods in drug development

Background:

  • The rise of biosimilar products necessitates robust quantitative evaluation methods.
  • Biological products exhibit inherent variability from manufacturing and environmental factors, complicating assessment compared to small-molecule drugs.
  • Existing methods may not fully capture the nuances of biological product variability.

Purpose of the Study:

  • To propose a novel quantitative estimate method for biosimilarity index.
  • To establish a method for calculating the lower bound of the biosimilarity index.
  • To introduce and compare approximations for simplicity and accuracy in biosimilarity assessment.

Main Methods:

  • Development of an estimation method for the biosimilarity index.
  • Utilizing the concept of reproducibility probability and assessing statistical power.
  • Proposing and comparing simplified approximation methods for practical application.

Main Results:

  • A new method for estimating the biosimilarity index and its lower bound has been developed.
  • The proposed method leverages reproducibility probability for a more nuanced assessment.
  • Approximations offer varying degrees of simplicity and accuracy, providing options for different scenarios.

Conclusions:

  • The proposed method offers a statistically sound approach to quantitative biosimilarity evaluation.
  • This framework enhances the assessment of biological products, considering their inherent variability.
  • The study contributes to more reliable and accurate biosimilar product development and approval.